WINNIPEG, Dec. 5, 2019 /CNW/ - Medicure Inc.
("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF),
a cardiovascular pharmaceutical company, today announced that it
has reached a settlement agreement with the purchaser of Medicure's
interests in Apicore with respect to the amounts heldback under the
Apicore sale agreement. A settlement agreement was reached under
which Medicure will receive a net payment of US$5.1 million in relation to the holdback.
About Medicure
Medicure is a pharmaceutical company focused on the development
and commercialization of therapies for the U.S. cardiovascular
market. The present focus of the Company is the marketing and
distribution of AGGRASTAT® (tirofiban
hydrochloride) injection, ZYPITAMAGTM (pitavastatin)
tablets and the ReDS™ device in the
United States, where they are sold through the Company's
U.S. subsidiary, Medicure Pharma Inc. For more information on
Medicure please visit www.medicure.com.
To be added to Medicure's e-mail list, please
visit:
http://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
View original
content:http://www.prnewswire.com/news-releases/medicure-announces-settlement-of-holdback-dispute-from-apicore-sale-300970400.html
SOURCE Medicure Inc.